Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Non-Current Assets (2017 - 2025)

KalVista Pharmaceuticals' Non-Current Assets history spans 11 years, with the latest figure at $9.1 million for Q2 2025.

  • On a quarterly basis, Non-Current Assets fell 6.53% to $9.1 million in Q2 2025 year-over-year; TTM through Apr 2025 was $35.0 million, a 12.84% decrease, with the full-year FY2025 number at $9.1 million, down 6.53% from a year prior.
  • Non-Current Assets hit $9.1 million in Q2 2025 for KalVista Pharmaceuticals, up from $8.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for KALV hit a ceiling of $10.9 million in Q2 2023 and a floor of $3.7 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $8.9 million across 4 years, with a median of $9.1 million in 2025.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 102.17% in 2021 and later fell 18.36% in 2024.
  • Tracing KALV's Non-Current Assets over 4 years: stood at $7.7 million in 2021, then skyrocketed by 30.82% to $10.1 million in 2023, then fell by 12.82% to $8.8 million in 2024, then grew by 2.75% to $9.1 million in 2025.
  • Business Quant data shows Non-Current Assets for KALV at $9.1 million in Q2 2025, $8.8 million in Q4 2024, and $8.6 million in Q4 2024.